MUMBAI, June 28 (Reuters) - Sun Pharmaceutical Industries (SUN.BO) will stop selling generic version of Sanofi-Aventis’ (SASY.PA) cancer drug Eloxatin in the United States after June 30 following a court order, the Indian drugmaker said.
In April, Sanofi-Aventis settled a patent law suit over Eloxatin with additional drugmakers, stopping them from selling their generic versions in the United States from June 30 until August 2012. [ID:nLDE635050]
Caraco Pharmaceutical Laboratories Ltd CPD.A, a unit of Sun Pharmaceutical, had said in March it had launched the generic version of anti-cancer drug oxaliplatin in injection form in the United States. [ID:nSGE62B07M] (Reporting by Sumeet Chatterjee)